



DOCKET NO.: ISHT-1004/HTS-0016US.P1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Kenneth W. Dobie and Erich Koller

Confirmation No.: 2946

Application No.: 10/714,796

Group Art Unit: 1635

Filing Date: November 17, 2003

Examiner: Not Yet Assigned

For: ANTISENSE MODULATION OF KINESIN-LIKE 1 EXPRESSION

EXPRESS MAIL LABEL NO: EV631244260US

DATE OF DEPOSIT: January 23, 2006

EV631244260US

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

- ☐ Certification in Accordance with § 1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers 14 - 16 listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of reference numbers 17 - 18 on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.


- ☐ The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

The references cited on the attached PTO-1449 form were cited in the International Search Report Written Opinion dated December 27, 2005 that was received in the corresponding PCT application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: January 23, 2006


Phillip A. Singer
Registration No. 40,176

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISHT-1004/HTS-0016US.P1		Application No. 10/714,796
	Applicant Kenneth W. Dobie and Erich Koller		
	Filing Date November 17, 2003		Group 1635
	Confirmation No. 2946		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	14	Agrawal S., et al., "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Molecular Med. Today</i> , 2000 , 6, 72-81	
	15	Branch, A.D., "A good antisense molecule is hard to find," <i>TIBS</i> , 1998 , 23, 45-50	
	16	Jen, K.-Y., et al., "Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies," <i>Stem Cells</i> , 2000 , 18, 307-319	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. ISHT-1004/HTS-0016US.P1		Application No. 10/714,796	
				Applicant Kenneth W. Dobie and Erich Koller			
				Filing Date November 17, 2003		Group 1635	
				Confirmation No. 2946			
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
	17	5,801,154	09/01/98	Baracchini, et al.	514	44	
	18	2004/0009156 A1	01/15/04	Reinhard, et al.	424	93.21	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation		
					YES	NO	
EXAMINER				DATE CONSIDERED			